-- Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.
The iShares Biotechnology ETF (IBB) decreased 0.4%.
In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After digesting Q1 2026 earnings, we increase our 12-month target price by $6 to $57, 8.3x our 2027 EPS estimate, a discount to the peer average of 10.9x, as weak growth prospects outweigh the benefits of limited competition in Hawaii. We raise our 2026 EPS estimate to $5.95 from $5.33 and 2027's to $6.84 from $5.94. Our revenue projections are $801M in 2026 and $858M in 2027. BOH's Q1 results showed positive momentum, with net interest income growing for the eighth straight quarter and credit quality remaining solid. Despite these strengths, we believe the stock is overvalued given weak fundamental growth trends. Loan balances have been flat Y/Y, while deposits have grown only 1% over four years. Furthermore, although BOH maintains strong capital levels (12.1% CET1 ratio), the bank faces unusual vulnerability to rising long-term interest rates due to significant unrealized losses in its securities portfolio. We note BOH's quarterly dividend has been stagnant at $0.70 since mid-2021.
Wedbush Securities on Monday raised the North American box office forecast for 2026, citing strong first-quarter growth and summer releases.The brokerage expects box office proceeds to rise 13% annually to $9.8 billion this year, up from 10% previously projected. First-quarter collections grew 25% year over year to $1.8 billion.CinemaCon, a trade show for the motion picture theater industry, was conducted in Las Vegas last week. The event showed strong studio slates and a focus on lengthening theatrical windows, Wedbush said."All of the studios came out this year with more confidence than last year," Wedbush analysts, including Alicia Reese, said.The deal between Warner Bros. Discovery (WBD) and Paramount Skydance (PSKY) dominated the event, with Paramount Chief Executive David Ellison promising a 45-day exclusive theatrical window upon deal completion and an output increase to 30 titles per year, Reese said.Theater operators have been demanding a 45-day minimum, Reuters reported last week. Movies staying in theaters longer drives more favorable economics across theatrical and streaming, according to the Wedbush note.Comcast's (CMCSA) Universal said it planned to extend the exclusive theatrical window to 45 days by 2027, compared with its current 17-day window that is seen moving to 35 days in 2026, Reese said.The summer slate, especially in the third quarter, "is shaping up very nicely," Reese said.Last week, B. Riley Securities raised its 2026 box office projections to $9.55 billion from $9.40 following a better-than-expected first quarter.Wedbush upgraded its 2027 box office growth estimate to 5% from 4%, at $10.2 billion.However, if the combined Paramount-Warner Bros. company cuts theatrical output, there could be some downside risk to the 2027 estimate, Reese said."That said, our current estimate does not anticipate that the combined studio reaching the company's stated goal of 30 total titles," Reese said.
NXP Semiconductors (NXPI) said late Monday its subsidiary, NXP, along with NXP USA and NXP Funding, has redeemed $750 million in outstanding 3.875% senior notes due June 2026, in accordance with the terms of the applicable indenture.